T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
T-knife has raised €93M across 1 funding round from 9 investors, most recently a Series B round in Aug 2021. Based in Berlin, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-08-02 | Series B | €93M |
| Andera Partners,CaaS Capital Management,Casdin Capital,Fidelity Management & Research Company LLC,LSP,Qatar Investment Authority+3 more |
| View deal → |
